Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of kidney failure, necessitating novel therapies to slow disease progression. The Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) trial is a prospective, multi-centre, international, double-blind, randomized, placebo-controlled phase III study evaluating metformin’s efficacy in reducing kidney function decline in ADPKD patients.
Fendo is a pain-relieving medicine that contains Diclofenac Sodium, a widely used ingredient for reducing pain and inflammation. It works by blocking certain chemicals in the body responsible for swelling and discomfort, making it particularly useful for conditions such as arthritis, muscle pain, back pain, and post-surgical recovery.
This 2025 review highlights the manner in which combination therapy has become the preferred treatment for chronic kidney disease (CKD) in diabetic and non-diabetic patients. CKD treatments have recently come up with new drugs that not only protect the kidneys but also lower the risk of cardiovascular complications and kidney failure.
The article discusses the potential use of targeted-release budesonide (TRF-budesonide) in treating IgA nephropathy (IgAN), a common kidney disease characterized by IgA deposits in the kidneys. IgAN can lead to end-stage renal disease, and current treatments like ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) aren’t always effective in slowing disease progression.
The FDA has approved Novo Nordisk’s Ozempic to treat chronic kidney disease (CKD) in patients with Type 2 diabetes, expanding its role beyond diabetes management. Previously used primarily for blood sugar control and weight loss, Ozempic can now help slow kidney function decline, reduce the risk of kidney failure, and lower the chances of death from cardiovascular disease in these patients.
Empagliflozin is a medication primarily used for diabetes treatment, but researchers have investigated its effects on uric acid levels in people with chronic kidney disease (CKD) through the EMPA-KIDNEY trial. This extensive study involved 6,609 patients with CKD, examining how empagliflozin affects uric acid levels, a naturally occurring substance that can cause gout when elevated. The trial was designed to compare patients taking empagliflozin against those taking a placebo over approximately two years. The researchers collected detailed data about kidney function, uric acid levels, and various other health markers throughout the study period.
